Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics

REGN POWR Grades

• REGN scores best on the Value dimension, with a Value rank ahead of 94.17% of US stocks.
• REGN's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
• REGN ranks lowest in Momentum; there it ranks in the 9th percentile.

REGN Stock Summary

• REGN has a market capitalization of $63,333,627,675 -- more than approximately 95.71% of US stocks.
• REGN's went public 30.59 years ago, making it older than 83.47% of listed US stocks we're tracking.
• As for revenue growth, note that REGN's revenue has grown 54.84% over the past 12 months; that beats the revenue growth of 87.57% of US companies in our set.
• Stocks that are quantitatively similar to REGN, based on their financial statements, market capitalization, and price volatility, are LRCX, VRTX, MU, CDNS, and SNPS.
• Visit REGN's SEC page to see the company's official filings. To visit the company's web site, go to www.regeneron.com.

REGN Valuation Summary

• In comparison to the median Healthcare stock, REGN's price/sales ratio is 48.9% lower, now standing at 5.8.
• REGN's price/sales ratio has moved down 24.1 over the prior 243 months.
• Over the past 243 months, REGN's EV/EBIT ratio has gone up 38.2.

Below are key valuation metrics over time for REGN.

REGN Growth Metrics

• Its year over year net cashflow from operations growth rate is now at 16.03%.
• The year over year price growth rate now stands at -13.18%.
• The 3 year cash and equivalents growth rate now stands at 182.76%.

Over the past 15 months, REGN's revenue has gone up $4,404,300,000.

The table below shows REGN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	12,384.1	2,271.9	6,205.4
2021-03-31	9,197.6	2,588.6	4,003.8
2020-12-31	8,497.1	2,618.1	3,513.2
2020-09-30	8,243.7	2,174.5	3,156
2020-06-30	7,998.1	2,986.1	2,983.5
2020-03-31	7,979.8	2,231	2,279.3

REGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• REGN has a Quality Grade of B, ranking ahead of 86.65% of graded US stocks.
• REGN's asset turnover comes in at 0.683 -- ranking 43rd of 680 Pharmaceutical Products stocks.
• JAZZ, AGLE, and VERU are the stocks whose asset turnover ratios are most correlated with REGN.

The table below shows REGN's key quality metrics over time.